Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LentiFlash is a proprietary **non-integrative lentiviral vector** RNA delivery platform developed by Flash Therapeutics for transient intracellular delivery of therapeutic RNA cargos. The technology uses **bacteriophage-lentiviral chimeras** to introduce RNA into target cells without genomic integration, enabling short-term protein expression and making it suitable for applications such as **gene editing**, **mRNA delivery**, **vaccination**, **immunotherapy**, and **regenerative medicine**. Rather than being a single fixed active substance, LentiFlash is a configurable delivery modality whose specific biological effect depends on the RNA payload; disclosed internal uses include programs in blood and liver diseases and an **APLN-VEGF-C mRNA** combination approach for **secondary lymphedema**.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on LentiFlash.